Breaking the Bottleneck of Affordability
Could the daunting costs of cell and gene therapies be reduced if research hospitals developed and processed therapies in house to treat their patients?
Vered Caplan | | Opinion
Advances in cell and gene therapies offer the potential to transform medicine. But current pricing structures are unsustainable – and they are severely limiting the introduction of new, potentially life-changing or life-saving therapeutics.
Though research and development in this sector is moving at an impressive rate, the complexities of scale for growing, sourcing and transporting cells and other components of cell and gene therapies are evident – and this is clearly feeding into costs.
Read the full article now
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.